Teva Pharmaceutical Industries (TEVA) Equity Ratio (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Equity Ratio across 18 years of filings, most recently posting 0.21 for Q1 2026.

• Quarterly Equity Ratio rose 25.92% year-over-year to 0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.21 (up 25.92% YoY) and the FY2025 annual result came in at 0.19, up 41.97% from the prior year.
• Equity Ratio rose to 0.21 in Q1 2026, from 0.19 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.22 in Q1 2022 and troughed at 0.14 in Q4 2024.
• A 5-year average of 0.18 and a median of 0.18 in 2025 frame the typical range for Equity Ratio.
• Annual changes were most pronounced in 2024 — Equity Ratio decreased 26.8% — and 2025, when it surged 41.97%.
• Tracing TEVA's Equity Ratio over 5 years: stood at 0.2 in 2022, then retreated by 4.33% to 0.19 in 2023, then retreated by 26.8% to 0.14 in 2024, then jumped by 41.97% to 0.19 in 2025, then advanced by 5.81% to 0.21 in 2026.
• Business Quant data shows TEVA's Equity Ratio at 0.21 in Q1 2026, 0.19 in Q4 2025, and 0.18 in Q3 2025.